179 related articles for article (PubMed ID: 19675719)
1. External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity.
Reinauer H; Wood WG
Ger Med Sci; 2005 May; 3():Doc02. PubMed ID: 19675719
[TBL] [Abstract][Full Text] [Related]
2. Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study.
van Rossum HH; Holdenrieder S; Ballieux BEPB; Badrick TC; Yun YM; Zhang C; Patel D; Thelen M; Song J; Wojtalewicz N; Unsworth N; Vesper HW; Cui W; Ramanathan LV; Sturgeon C; Meng QH
Clin Chem; 2024 Apr; 70(4):669-679. PubMed ID: 38385453
[TBL] [Abstract][Full Text] [Related]
3. [National external quality assessment and comparability of assays for tumor markers measurements].
Zhang JT; Zhang CB; Ma R; Zhao HJ; Wang J; Wang ZG; Chen WX
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):993-7. PubMed ID: 20646652
[TBL] [Abstract][Full Text] [Related]
4. Standardization of tumor markers - priorities identified through external quality assessment.
Sturgeon C
Scand J Clin Lab Invest Suppl; 2016; 245():S94-9. PubMed ID: 27542005
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of tumour markers.
Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Evaluation of AFP and CEA External Proficiency Testing Reveals Need for Method Harmonization.
Wojtalewicz N; Vierbaum L; Kaufmann A; Schellenberg I; Holdenrieder S
Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370914
[TBL] [Abstract][Full Text] [Related]
7. Immunoassay of CEA, CA 19-9, CA 125, and CA 15-3 on the automated systems ES 300 and ES 600: methodological evaluation from a multicentre collaborative study.
Zucchelli GC; Pilo A; Jaworek D; Masini S; Chiesa MR
Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):875-9. PubMed ID: 1489864
[TBL] [Abstract][Full Text] [Related]
8. Interlaboratory surveys of the determination of tumour markers scatter and repeatability of the results.
Kruse R; Geilenkeuser WJ; Röhle G
Eur J Clin Chem Clin Biochem; 1993 Mar; 31(3):139-46. PubMed ID: 7683915
[TBL] [Abstract][Full Text] [Related]
9. Influence of cardiopulmonary resuscitation on levels of tumour markers.
Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
[TBL] [Abstract][Full Text] [Related]
10. Multicentre tumour marker reference range study.
Wilson AP; Van Dalen A; Sibley PE; Kasper LA; Durham AP; el Shami AS
Anticancer Res; 1999; 19(4A):2749-52. PubMed ID: 10470234
[TBL] [Abstract][Full Text] [Related]
11. Comparability of method results and performance in a national external quality assessment scheme between 1993 and 2003 using thyroid associated analytes as examples.
Wood WG; Hanke R; Reinauer H
Clin Lab; 2004; 50(5-6):333-46. PubMed ID: 15209442
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
Hing JX; Mok CW; Tan PT; Sudhakar SS; Seah CM; Lee WP; Tan SM
Breast; 2020 Aug; 52():95-101. PubMed ID: 32485607
[TBL] [Abstract][Full Text] [Related]
13. Status of External Quality Assessment on Tumor Markers in China.
Xiao Y; Zhang C; Zhao H; Wang W; He F; Zhong K; Yuan S; Wang Z
Clin Lab; 2015; 61(10):1383-90. PubMed ID: 26642698
[TBL] [Abstract][Full Text] [Related]
14. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
15. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
16. Has the introduction of the European Parliament Directive 98/79/EC from 1998-10-27--concerning in-vitro diagnostic devices (IVD-directive) influenced performance of hormone immunoassay kits in terms of precision and accuracy? Results from selected external quality assessment (EQA) schemes between 1993 and 2008.
Wood WG
Clin Lab; 2009; 55(3-4):86-105. PubMed ID: 19462931
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J
Ann Oncol; 1995 Jul; 6(6):581-7. PubMed ID: 8573538
[TBL] [Abstract][Full Text] [Related]
20. Comparability of method results and performance in a national external quality assessment scheme between 1993 and 2003 using thyroid associated antibodies as examples.
Wood WG; Hanke R
Clin Lab; 2004; 50(3-4):209-21. PubMed ID: 15074477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
